Clinical Trials Browser

OTHER × Observational × CTLA-4 Antigen × Clear all

NCT04659343 2026-05-04

TDM for Optimized Outcome in Patients With mRCC.

Kidney Neoplasms, Drug-Related Side Effects and Adverse Reactions